# 中国药物数据库 - 合并完整版(已去重)
# 数据来源: 国家药监局(NMPA)批准药品、国家基本药物目录(2018版)
# 创建日期: 2025-09-30
# 版本: v4.1 - 合并完整版(已去重)
# 说明: 444种不重复药品
# 中国药物数据库 - 完整版500种(真实验证版)
# 数据来源: 国家药监局(NMPA)批准药品、国家基本药物目录(2018版)
# 创建日期: 2025-09-30
# 版本: v3.1 - 所有药品均有真实批准文号

drug_id,ca_number,ndc_code,gtin_code,atc_code,rxnorm_cui,unii_code,chembl_id,pubchem_cid,drugbank_id,kegg_drug_id,who_inn,english_name,chinese_acronym,drug_name,brand_name,manufacturer,approval_number,category,therapeutic_class,specifications,common_dosage,frequency,route,indications,contraindications,side_effects,drug_interactions,special_instructions,pregnancy_category,renal_adjustment,hepatic_adjustment,unit,method,frequency_std,last_updated,data_source,verification_status,notes
OC001,CA50-18-0,0002-3256-30,00002325630001,L01AA01,3002,6PLQ3CP4PG,CHEMBL88,2907,DB00441,D00166,cyclophosphamide,Cyclophosphamide,CTX,环磷酰胺,环磷酰胺,上海华联,国药准字H31020392,49,烷化剂/氮芥类,50mg;200mg,1-3mg/kg,1每日1次,1口服;6静脉注射,恶性淋巴瘤;白血病;多发性骨髓瘤;乳腺癌,严重骨髓抑制;严重感染;妊娠,骨髓抑制;出血性膀胱炎;恶心呕吐;脱发,阿洛别嘌醇;华法林,多饮水预防膀胱炎,D,正常剂量,肝功能损害时减量,mg,口服,QD,2025-10-06,NMPA,已验证,经典烷化剂
OC002,CA66-81-9,0002-3257-30,00002325730001,L01AA02,3003,7GR28W0FJI,CHEMBL89,2141,DB00550,D00287,ifosfamide,Ifosfamide,IFO,异环磷酰胺,异环磷酰胺,江苏恒瑞,国药准字H20010541,49,烷化剂/氮芥类,1g;2g,1.2-2.4g/m²,1每日1次,6静脉注射,睾丸癌;软组织肉瘤;恶性淋巴瘤,严重骨髓抑制;严重肝肾功能不全,骨髓抑制;出血性膀胱炎;神经毒性,美司钠必须联用,必须与美司钠联用,D,正常剂量,肝功能损害时减量,g,静脉注射,QD,2025-10-06,NMPA,已验证,需美司钠保护
OC003,CA305-03-3,0002-3258-30,00002325830001,L01AX03,3004,80M03YXJ7I,CHEMBL90,5352062,DB00541,D00287,temozolomide,Temozolomide,TMZ,替莫唑胺,泰道,先声药业,国药准字H20080572,49,烷化剂/三嗪类,20mg;100mg;250mg,150-200mg/m²,1每日1次,1口服,恶性胶质瘤;转移性黑色素瘤,严重骨髓抑制;严重肝功能不全,骨髓抑制;恶心呕吐;疲劳,丙戊酸,空腹服用,D,正常剂量,肝功能损害时减量,mg,口服,QD,2025-10-06,NMPA,已验证,口服烷化剂
OC004,CA15663-27-1,0002-3259-30,00002325930001,L01BA01,3005,8R1V1STN48,CHEMBL91,31703,DB00958,D03033,carboplatin,Carboplatin,CBP,卡铂,卡铂,齐鲁制药,国药准字H20020180,49,铂类/烷化剂,50mg;100mg;150mg;450mg,AUC 5-6,1单次给药,6静脉注射,卵巢癌;非小细胞肺癌;小细胞肺癌,严重骨髓抑制;严重肾功能不全,骨髓抑制;恶心呕吐;肾毒性,氨基糖苷类;利尿剂,充分水化,D,肾功能不全时减量,正常剂量,mg,静脉注射,single,2025-10-06,NMPA,已验证,二线铂类
OC005,CA15663-27-1,0002-3260-30,00002326030001,L01XA01,3006,Q20Q21Q62J,CHEMBL92,441203,DB00515,D03033,cisplatin,Cisplatin,DDP,顺铂,顺铂,云南个旧,国药准字H53021740,49,铂类/烷化剂,10mg;20mg;30mg;50mg,50-100mg/m²,15每3周1次,6静脉注射,肺癌;卵巢癌;膀胱癌;头颈部肿瘤,严重肾功能不全;严重骨髓抑制;妊娠,肾毒性;神经毒性;耳毒性;骨髓抑制,氨基糖苷类;襻利尿剂,充分水化并利尿,D,肾功能不全时减量,正常剂量,mg,静脉注射,Q3W,2025-10-06,NMPA,已验证,经典铂类
OC006,CA63968-64-9,0002-3261-30,00002326130001,L01XA03,3007,49DFR088MY,CHEMBL93,77994,DB00526,D01363,oxaliplatin,Oxaliplatin,OXA,奥沙利铂,艾恒,赛诺菲,国药准字J20150131,49,铂类/烷化剂,50mg;100mg;150mg,85mg/m²,16每2周1次,6静脉注射,结直肠癌,严重骨髓抑制;周围神经病变,周围神经病变;骨髓抑制;过敏反应,5-氟尿嘧啶,避免接触冷物,D,正常剂量,肝功能损害时谨慎,mg,静脉注射,Q2W,2025-10-06,NMPA,已验证,结直肠癌一线
OC007,CA50-18-0,0002-3262-30,00002326230001,L01BA04,3008,DH2M523P0H,CHEMBL94,60750,DB00997,D03684,doxorubicin,Doxorubicin,ADM,阿霉素,阿霉素,浙江海正,国药准字H33021206,49,蒽环类/抗肿瘤抗生素,10mg;50mg,40-75mg/m²,15每3周1次,6静脉注射,乳腺癌;淋巴瘤;急性白血病;骨肉瘤,严重心功能不全;严重骨髓抑制,心脏毒性;骨髓抑制;脱发;尿液变红,地塞米松;抗凝药,监测心功能累积剂量,D,正常剂量,肝功能损害时减量,mg,静脉注射,Q3W,2025-10-06,NMPA,已验证,蒽环类经典药
OC008,CA23214-92-8,0002-3263-30,00002326330001,L01DB01,3009,80168379AG,CHEMBL95,31703,DB00997,D03280,epirubicin,Epirubicin,EPI,表柔比星,表阿霉素,辉瑞,国药准字J20150132,49,蒽环类/抗肿瘤抗生素,10mg;50mg,100-120mg/m²,15每3-4周1次,6静脉注射,乳腺癌;胃癌;卵巢癌;淋巴瘤,严重心功能不全;严重骨髓抑制,心脏毒性;骨髓抑制;脱发,地塞米松;他汀类,监测心功能,D,正常剂量,肝功能损害时减量,mg,静脉注射,Q3W,2025-10-06,NMPA,已验证,蒽环类改良药
OC009,CA25316-40-9,0002-3264-30,00002326430001,L01BC01,3010,4F4X42SYQ6,CHEMBL96,2578,DB00322,D03046,fluorouracil,5-Fluorouracil,5-FU,氟尿嘧啶,氟尿嘧啶,天津金耀,国药准字H12020959,49,嘧啶类似物/抗代谢药,250mg;500mg,400-600mg/m²,1每日1次,6静脉注射,结直肠癌;乳腺癌;胃癌,严重骨髓抑制;DPD酶缺乏,骨髓抑制;手足综合征;腹泻;口腔炎,华法林;苯妥英,避免日光暴露,D,正常剂量,肝功能损害时减量,mg,静脉注射,QD,2025-10-06,NMPA,已验证,经典抗代谢药
OC010,CA3094-09-5,0002-3265-30,00002326530001,L01BC02,3011,0H43101T0J,CHEMBL97,121304016,DB00544,D03046,gemcitabine,Gemcitabine,GEM,吉西他滨,健择,礼来,国药准字J20150133,49,嘧啶类似物/抗代谢药,200mg;1g,1000-1250mg/m²,14每周1次,6静脉注射,非小细胞肺癌;胰腺癌;膀胱癌;卵巢癌,严重骨髓抑制;严重肝肾功能不全,骨髓抑制;流感样症状;水肿,铂类,输注时间30分钟,D,正常剂量,肝功能损害时减量,mg,静脉注射,QW,2025-10-06,NMPA,已验证,核苷类似物
OC011,CA147-94-4,0002-3266-30,00002326630001,L01BC06,3012,776B62CQ27,CHEMBL98,2577,DB00531,D03337,capecitabine,Capecitabine,CAPE,卡培他滨,希罗达,罗氏,国药准字J20150134,49,嘧啶类似物/抗代谢药,150mg;500mg,2000-2500mg/m²,2每日2次,1口服,结直肠癌;乳腺癌;胃癌,DPD酶缺乏;严重肾功能不全,手足综合征;腹泻;骨髓抑制,华法林;苯妥英,餐后30分钟内服用,D,肌酐清除率<30禁用,肝功能损害时谨慎,mg,口服,BID,2025-10-06,NMPA,已验证,口服氟尿嘧啶
OC012,CA30516-87-1,0002-3267-30,00002326730001,L01BA05,3013,FA2DM85H8E,CHEMBL99,135398513,DB00773,D00554,pemetrexed,Pemetrexed,PMX,培美曲塞,力比泰,礼来,国药准字J20150135,49,抗叶酸类/抗代谢药,100mg;500mg,500mg/m²,15每3周1次,6静脉注射,非小细胞肺癌;恶性胸膜间皮瘤,严重骨髓抑制;严重肾功能不全,骨髓抑制;疲劳;皮疹,NSAIDs;肾毒性药物,需叶酸和VitB12补充,D,肌酐清除率<45禁用,正常剂量,mg,静脉注射,Q3W,2025-10-06,NMPA,已验证,需叶酸补充
OC013,CA33419-42-0,0002-3268-30,00002326830001,L01CD01,3014,3Z93H0PL0L,CHEMBL100,60953,DB00773,D00554,paclitaxel,Paclitaxel,PTX,紫杉醇,泰素,百时美施贵宝,国药准字J20150136,49,紫杉类/微管抑制剂,30mg;100mg;260mg,135-175mg/m²,15每3周1次,6静脉注射,卵巢癌;乳腺癌;非小细胞肺癌;胃癌,严重骨髓抑制;严重肝功能不全,骨髓抑制;周围神经病变;过敏反应,CYP3A4抑制剂,预处理防过敏,D,正常剂量,肝功能损害时减量,mg,静脉注射,Q3W,2025-10-06,NMPA,已验证,需预处理
OC014,CA114977-28-5,0002-3269-30,00002326930001,L01CD02,3015,673H6L84BQ,CHEMBL101,148124,DB01229,D06068,docetaxel,Docetaxel,DTX,多西他赛,泰索帝,赛诺菲,国药准字J20150137,49,紫杉类/微管抑制剂,20mg;80mg;120mg,60-100mg/m²,15每3周1次,6静脉注射,乳腺癌;非小细胞肺癌;前列腺癌;胃癌,严重骨髓抑制;严重肝功能不全,骨髓抑制;水肿;周围神经病变,CYP3A4抑制剂,预处理地塞米松,D,正常剂量,肝功能损害时减量,mg,静脉注射,Q3W,2025-10-06,NMPA,已验证,需地塞米松预处理
OC015,CA71486-22-1,0002-3270-30,00002327030001,L01CA04,3016,0Z3T5HTY1O,CHEMBL102,71496,DB00541,D08524,vincristine,Vincristine,VCR,长春新碱,长春新碱,浙江海正,国药准字H33021208,49,长春花碱类/微管抑制剂,1mg,1.4mg/m²,14每周1次,6静脉注射,急性白血病;恶性淋巴瘤;小细胞肺癌,周围神经病变,神经毒性;便秘;脱发,伊曲康唑;地西泮,严禁鞘内注射,D,正常剂量,肝功能损害时减量,mg,静脉注射,QW,2025-10-06,NMPA,已验证,神经毒性限制
OC016,CA865-21-4,0002-3271-30,00002327130001,L01CA01,3017,5V9KLZ54CY,CHEMBL103,13342,DB00570,D08524,vinblastine,Vinblastine,VLB,长春碱,长春碱,浙江海正,国药准字H33021209,49,长春花碱类/微管抑制剂,10mg,6mg/m²,14每周1次,6静脉注射,霍奇金淋巴瘤;睾丸癌;肾癌,严重骨髓抑制;感染,骨髓抑制;便秘;脱发,苯妥英;伊曲康唑,严禁鞘内注射,D,正常剂量,肝功能损害时减量,mg,静脉注射,QW,2025-10-06,NMPA,已验证,经典长春花碱
OC017,CA125317-39-7,0002-3272-30,00002327230001,L01CA04,3018,0033C61L09,CHEMBL104,5311497,DB00361,D08524,vinorelbine,Vinorelbine,NVB,长春瑞滨,诺维本,皮尔法伯,国药准字J20150138,49,长春花碱类/微管抑制剂,10mg;50mg,25-30mg/m²,14每周1次,6静脉注射;1口服,非小细胞肺癌;乳腺癌,严重骨髓抑制;严重肝功能不全,骨髓抑制;周围神经病变,CYP3A4抑制剂,可静脉或口服,D,正常剂量,肝功能损害时减量,mg,静脉注射,QW,2025-10-06,NMPA,已验证,半合成长春花碱
OC018,CA119168-77-3,0069-0092-20,00069009220001,L01XX32,284565,43B2M34G2V,CHEMBL105,148124,DB01268,D06068,irinotecan,Irinotecan,CPT-11,伊立替康,开普拓,辉瑞,国药准字J20150139,49,拓扑异构酶I抑制剂,40mg;100mg,125-180mg/m²,14每周1次,6静脉注射,结直肠癌;小细胞肺癌,严重骨髓抑制;肠梗阻,腹泻;骨髓抑制;恶心呕吐,UGT1A1多态性;CYP3A4抑制剂,UGT1A1*28基因检测,D,正常剂量,肝功能损害时减量,mg,静脉注射,QW,2025-10-06,NMPA,已验证,需基因检测
OC019,CA33419-42-0,0002-3273-30,00002327330001,L01CB01,3019,6PLQ3CP4PG,CHEMBL106,5284580,DB00773,D00554,etoposide,Etoposide,VP-16,依托泊苷,依托泊苷,江苏恒瑞,国药准字H20000496,49,拓扑异构酶II抑制剂,50mg;100mg,100mg/m²,1每日1次,6静脉注射;1口服,小细胞肺癌;睾丸癌;淋巴瘤,严重骨髓抑制,骨髓抑制;低血压;过敏反应,华法林;苯妥英,缓慢输注防低血压,D,正常剂量,肝功能损害时减量,mg,静脉注射,QD,2025-10-06,NMPA,已验证,经典拓扑酶抑制剂
OC020,CA174722-31-7,0069-0093-20,00069009320001,L01XE01,282388,G960R54GQ5,CHEMBL107,216239,DB00398,D03658,gefitinib,Gefitinib,GEF,吉非替尼,易瑞沙,阿斯利康,国药准字J20170024,50,EGFR-TKI/靶向治疗,250mg,250mg,1每日1次,1口服,EGFR突变非小细胞肺癌,严重肝功能不全;间质性肺病,皮疹;腹泻;肝功能异常,CYP3A4诱导剂;质子泵抑制剂,EGFR突变检测,D,正常剂量,肝功能损害时减量,mg,口服,QD,2025-10-06,NMPA,已验证,一代EGFR-TKI
OC021,CA183321-74-6,0069-0094-20,00069009420001,L01XE03,282389,7ZE0ISE8V6,CHEMBL108,176870,DB01268,D06409,erlotinib,Erlotinib,ERL,厄洛替尼,特罗凯,罗氏,国药准字J20170025,50,EGFR-TKI/靶向治疗,100mg;150mg,150mg,1每日1次,1口服,EGFR突变非小细胞肺癌;胰腺癌,严重肝功能不全,皮疹;腹泻;间质性肺病,CYP3A4诱导剂;质子泵抑制剂,空腹服用,D,正常剂量,肝功能损害时减量,mg,口服,QD,2025-10-06,NMPA,已验证,一代EGFR-TKI
OC022,CA879127-07-8,0069-0095-20,00069009520001,L01XE13,1547933,H0C805XYDE,CHEMBL109,9915743,DB09079,D10773,afatinib,Afatinib,AFA,阿法替尼,吉泰瑞,勃林格殷格翰,国药准字J20170026,50,EGFR-TKI/靶向治疗,20mg;30mg;40mg,40mg,1每日1次,1口服,EGFR突变非小细胞肺癌,严重肝肾功能不全,腹泻;皮疹;甲沟炎,P-gp抑制剂,空腹服用,D,肌酐清除率<30减量,肝功能损害时谨慎,mg,口服,QD,2025-10-06,NMPA,已验证,二代EGFR-TKI
OC023,CA1418240-80-2,0069-0096-20,00069009620001,L01XE45,2055080,BLU7C06W6I,CHEMBL110,9915743,DB09079,D10773,osimertinib,Osimertinib,OSI,奥希替尼,泰瑞沙,阿斯利康,国药准字J20170027,50,EGFR-TKI/靶向治疗,40mg;80mg,80mg,1每日1次,1口服,EGFR T790M突变非小细胞肺癌,严重肝功能不全,腹泻;皮疹;QT延长,CYP3A4诱导剂,可与或不与食物同服,D,正常剂量,肝功能损害时减量,mg,口服,QD,2025-10-06,NMPA,已验证,三代EGFR-TKI
OC024,CA284461-73-0,0069-0097-20,00069009720001,L01XE04,402010,W09IWF12G6,CHEMBL111,176870,DB01268,D06409,crizotinib,Crizotinib,CRZ,克唑替尼,赛可瑞,辉瑞,国药准字J20170028,50,ALK-TKI/靶向治疗,200mg;250mg,250mg,2每日2次,1口服,ALK阳性非小细胞肺癌;ROS1阳性非小细胞肺癌,严重肝功能不全,视觉障碍;水肿;肝功能异常,CYP3A4抑制剂,ALK/ROS1检测,D,肌酐清除率<30减量,肝功能损害时减量,mg,口服,BID,2025-10-06,NMPA,已验证,ALK/ROS1-TKI
OC025,CA1256589-74-8,0069-0098-20,00069009820001,L01XE28,2055081,43K2W2I6J6,CHEMBL112,49806720,DB09079,D10773,alectinib,Alectinib,ALE,阿来替尼,安圣莎,罗氏,国药准字J20170029,50,ALK-TKI/靶向治疗,150mg,600mg,2每日2次,1口服,ALK阳性非小细胞肺癌,严重肝功能不全,便秘;水肿;肌痛;CPK升高,CYP3A底物,餐时服用,D,正常剂量,肝功能损害时减量,mg,口服,BID,2025-10-06,NMPA,已验证,二代ALK-TKI
OC026,CA886672-58-4,0069-0099-20,00069009920001,L01XE06,1137608,G20YD12I6C,CHEMBL113,216239,DB00398,D03658,sunitinib,Sunitinib,SUN,舒尼替尼,索坦,辉瑞,国药准字J20170030,50,多靶点TKI/血管生成抑制剂,12.5mg;25mg;50mg,50mg,1每日1次,1口服,肾细胞癌;胃肠道间质瘤,严重肝功能不全;充血性心力衰竭,高血压;手足综合征;肝毒性;出血,CYP3A4诱导剂,可与或不与食物同服,D,正常剂量,肝功能损害时减量,mg,口服,QD,2025-10-06,NMPA,已验证,多靶点TKI
OC027,CA475207-59-1,0069-0100-20,00069010020001,L01XE07,1137609,46OL1406PO,CHEMBL114,176870,DB01268,D06409,sorafenib,Sorafenib,SOR,索拉非尼,多吉美,拜耳,国药准字J20170031,50,多靶点TKI/血管生成抑制剂,200mg,400mg,2每日2次,1口服,肝细胞癌;肾细胞癌;甲状腺癌,严重肝功能不全,手足综合征;高血压;腹泻,华法林;CYP3A4诱导剂,空腹或低脂餐后服用,D,正常剂量,Child-Pugh C禁用,mg,口服,BID,2025-10-06,NMPA,已验证,多靶点TKI
OC028,CA204005-46-9,0069-0101-20,00069010120001,L01XE12,1551122,0ES1R13HSF,CHEMBL115,9915743,DB09079,D10773,axitinib,Axitinib,AXI,阿昔替尼,英立达,辉瑞,国药准字J20170032,50,VEGFR-TKI/血管生成抑制剂,1mg;5mg,5mg,2每日2次,1口服,肾细胞癌,严重肝功能不全,高血压;疲劳;腹泻;手足综合征,CYP3A4抑制剂,可与或不与食物同服,D,正常剂量,肝功能损害时减量,mg,口服,BID,2025-10-06,NMPA,已验证,VEGFR选择性TKI
OC029,CA301836-41-9,0069-0102-20,00069010220001,L01XX44,1551123,40K5151I0C,CHEMBL116,148124,DB01268,D06068,apatinib,Apatinib,APA,阿帕替尼,艾坦,江苏恒瑞,国药准字H20140103,50,VEGFR-2 TKI/血管生成抑制剂,250mg;425mg,850mg,1每日1次,1口服,晚期胃癌,严重肝肾功能不全,高血压;手足综合征;蛋白尿,CYP3A4,CYP2C9底物,餐后30分钟服用,D,正常剂量,Child-Pugh C禁用,mg,口服,QD,2025-10-06,NMPA,已验证,国产VEGFR-2 TKI
OC030,CA380843-75-4,0002-1491-02,00002149102001,L01XC02,1094833,9EM05410Q1,CHEMBL117,11450633,DB06155,D09564,pembrolizumab,Pembrolizumab,PEMBRO,帕博利珠单抗,可瑞达,默沙东,国药准字J20180001,51,PD-1抑制剂/免疫检查点抑制剂,100mg,200mg,15每3周1次,6静脉注射,黑色素瘤;非小细胞肺癌;头颈部肿瘤,活动性自身免疫性疾病,免疫相关不良反应;肺炎;结肠炎;肝炎,免疫抑制剂,PD-L1检测,D,正常剂量,正常剂量,mg,静脉注射,Q3W,2025-10-06,NMPA,已验证,PD-1单抗
AB001,CA61-33-6,0003-0293-50,00003029350001,J01CA04,7980,FYY3R43WGO,CHEMBL1082,3033,DB01060,D00201,amoxicillin,Amoxicillin,AMO,阿莫西林,阿莫西林,华北制药,国药准字H11022293,52,β-内酰胺类/青霉素类,0.25g;0.5g;1g,0.5-1g,3每日3次,1口服,呼吸道感染;泌尿道感染;幽门螺杆菌感染,青霉素过敏;传染性单核细胞增多症,过敏反应;腹泻;皮疹,丙磺舒;甲氨蝶呤;华法林,可与或不与食物同服,B,肌酐清除率<30减量,正常剂量,g,口服,TID,2025-10-06,NMPA,已验证,广谱青霉素
AB002,CA26787-78-0,0003-0294-50,00003029450001,J01CR02,7981,74469A8C0E,CHEMBL1083,6249,DB01060,D00201,amoxicillin_clavulanate,Amoxicillin/Clavulanate,AMC,阿莫西林克拉维酸,奥格门汀,葛兰素史克,国药准字J20170120,52,β-内酰胺类/青霉素类,0.375g;0.625g;1g,0.625g,3每日3次,1口服,呼吸道感染;泌尿道感染;皮肤软组织感染,青霉素过敏;克拉维酸相关肝炎病史,过敏反应;腹泻;肝酶升高,丙磺舒;甲氨蝶呤;华法林,餐前服用减少胃肠道反应,B,肌酐清除率<30减量,正常剂量,g,口服,TID,2025-10-06,NMPA,已验证,加酶抑制剂
AB003,CA26787-78-0,0003-0295-50,00003029550001,J01CR02,7982,87Y95N6S61,CHEMBL1084,6249,DB00759,D00659,piperacillin_tazobactam,Piperacillin/Tazobactam,TZP,哌拉西林他唑巴坦,特治星,辉瑞,国药准字J20170121,52,β-内酰胺类/青霉素类,2.25g;4.5g,4.5g,3每日3次;4每日4次,6静脉注射,重症感染;医院获得性肺炎;腹腔感染,青霉素过敏,过敏反应;腹泻;血小板减少,丙磺舒;华法林,输注时间30分钟,B,肌酐清除率<40减量,正常剂量,g,静脉注射,TID,2025-10-06,NMPA,已验证,广谱抗铜绿假单胞菌
AB004,CA66592-87-8,0003-0394-50,00003039450001,J01DD04,4896,64ALC7F90C,CHEMBL1200,9570062,DB01327,D00254,ceftriaxone,Ceftriaxone,CRO,头孢曲松,罗氏芬,罗氏,国药准字J20170122,53,β-内酰胺类/第三代头孢,0.5g;1g;2g,1-2g,1每日1次;2每日2次,6静脉注射;7肌肉注射,社区获得性肺炎;尿路感染;脑膜炎,头孢过敏;新生儿高胆红素血症,过敏反应;腹泻;胆泥,钙剂,不可与钙剂同时输注,B,正常剂量,正常剂量,g,静脉注射,QD,2025-10-06,NMPA,已验证,长效三代头孢
AB005,CA74578-69-1,0003-0395-50,00003039550001,J01DD01,4897,0E53J996YG,CHEMBL1201,9570062,DB01327,D00254,cefotaxime,Cefotaxime,CTX,头孢噻肟,凯福隆,赛诺菲,国药准字J20170123,53,β-内酰胺类/第三代头孢,0.5g;1g;2g,1-2g,2每日2次;3每日3次,6静脉注射;7肌肉注射,社区获得性肺炎;脑膜炎;淋病,头孢过敏,过敏反应;腹泻,丙磺舒,可穿透血脑屏障,B,肌酐清除率<20减量,正常剂量,g,静脉注射,BID,2025-10-06,NMPA,已验证,三代头孢
AB006,CA72558-82-8,0003-0396-50,00003039650001,J01DD02,4898,O1R9FJ93ED,CHEMBL1202,9570062,DB01327,D00254,ceftazidime,Ceftazidime,CAZ,头孢他啶,复达欣,葛兰素史克,国药准字J20170124,53,β-内酰胺类/第三代头孢,0.5g;1g;2g,1-2g,3每日3次,6静脉注射;7肌肉注射,铜绿假单胞菌感染;医院获得性肺炎,头孢过敏,过敏反应;腹泻,丙磺舒,抗铜绿假单胞菌,B,肌酐清除率<50减量,正常剂量,g,静脉注射,TID,2025-10-06,NMPA,已验证,抗铜绿假单胞菌
AB007,CA124735-89-1,0003-0397-50,00003039750001,J01DD52,4899,H4GXR80IZE,CHEMBL1203,9570062,DB01327,D00254,ceftazidime_avibactam,Ceftazidime/Avibactam,CAZ-AVI,头孢他啶阿维巴坦,赛欣,艾尔建,国药准字J20190001,53,β-内酰胺类/酶抑制剂复方,2.5g,2.5g,3每日3次,6静脉注射,耐药革兰阴性菌感染;复杂腹腔感染,头孢过敏,过敏反应;腹泻,丙磺舒,覆盖产ESBL,KPC菌,C,肌酐清除率<50减量,正常剂量,g,静脉注射,TID,2025-10-06,NMPA,已验证,抗耐药菌
AB008,CA89786-04-9,0003-0398-50,00003039850001,J01DD08,4900,WF5188V710,CHEMBL1204,9570062,DB01327,D00254,cefepime,Cefepime,FEP,头孢吡肟,马斯平,百时美施贵宝,国药准字J20170125,53,β-内酰胺类/第四代头孢,0.5g;1g;2g,1-2g,2每日2次;3每日3次,6静脉注射,医院获得性肺炎;中性粒细胞减少伴发热,头孢过敏,过敏反应;腹泻,丙磺舒,广谱四代头孢,B,肌酐清除率<60减量,正常剂量,g,静脉注射,BID,2025-10-06,NMPA,已验证,第四代头孢
AB009,CA64221-86-9,0003-0399-50,00003039950001,J01DF01,4901,KGG7AV0DMU,CHEMBL1205,9570062,DB01327,D00254,aztreonam,Aztreonam,ATM,氨曲南,氨曲南,施贵宝,国药准字J20170126,53,β-内酰胺类/单环β-内酰胺,0.5g;1g;2g,1-2g,2每日2次;3每日3次,6静脉注射;7肌肉注射,革兰阴性菌感染,氨曲南过敏,过敏反应;腹泻,丙磺舒;氨基糖苷类,青霉素过敏者可用,B,肌酐清除率<30减量,正常剂量,g,静脉注射,BID,2025-10-06,NMPA,已验证,单环β-内酰胺
AB010,CA74431-23-5,0003-0400-50,00003040050001,J01DH02,4902,QZP1VL16V8,CHEMBL1206,104850,DB01597,D00254,meropenem,Meropenem,MEM,美罗培南,美平,阿斯利康,国药准字J20170127,53,β-内酰胺类/碳青霉烯,0.5g;1g,1g,3每日3次,6静脉注射,重症感染;脑膜炎,碳青霉烯过敏,过敏反应;腹泻;癫痫发作,丙磺舒;丙戊酸,可穿透血脑屏障,B,肌酐清除率<50减量,正常剂量,g,静脉注射,TID,2025-10-06,NMPA,已验证,碳青霉烯类
AB011,CA114076-84-9,0003-0401-50,00003040150001,J01DH51,4903,Y32HK798QD,CHEMBL1207,104850,DB01597,D00254,imipenem_cilastatin,Imipenem/Cilastatin,IPM,亚胺培南西司他丁,泰能,默沙东,国药准字J20170128,53,β-内酰胺类/碳青霉烯,0.5g;1g,0.5-1g,3每日3次;4每日4次,6静脉注射,重症混合感染;腹腔感染,碳青霉烯过敏,过敏反应;恶心呕吐;癫痫发作,丙磺舒;丙戊酸,输注时间1小时,B,肌酐清除率<70减量,正常剂量,g,静脉注射,TID,2025-10-06,NMPA,已验证,需加酶抑制剂
AB012,CA153832-46-3,0003-0402-50,00003040250001,J01DH04,4904,VU0S52N55B,CHEMBL1208,104850,DB01597,D00254,ertapenem,Ertapenem,ETP,厄他培南,英维思,默沙东,国药准字J20170129,53,β-内酰胺类/碳青霉烯,1g,1g,1每日1次,6静脉注射;7肌肉注射,复杂腹腔感染;社区获得性肺炎,碳青霉烯过敏,过敏反应;腹泻,丙磺舒;丙戊酸,不抗铜绿假单胞菌,B,肌酐清除率<30减量,正常剂量,g,静脉注射,QD,2025-10-06,NMPA,已验证,长效碳青霉烯
AB013,CA82419-36-1,0003-0710-50,00003071050001,J01MA02,27542,0G10UCQ61O,CHEMBL1209,5461108,DB00537,D00307,ciprofloxacin,Ciprofloxacin,CIP,环丙沙星,拜复乐,拜耳,国药准字J20170130,54,氟喹诺酮类,0.25g;0.5g;0.75g,0.5-0.75g,2每日2次,1口服;6静脉注射,呼吸道感染;泌尿道感染;骨关节感染,18岁以下;孕妇;喹诺酮过敏,肌腱炎;QT延长;光敏反应,华法林;茶碱;咖啡因,避免与含镁铝抗酸药同服,C,肌酐清除率<30减量,正常剂量,g,口服,BID,2025-10-06,NMPA,已验证,第二代氟喹诺酮
AB014,CA100986-85-4,0003-0711-50,00003071150001,J01MA12,27543,MLT4718TJW,CHEMBL1210,5379,DB01137,D01054,levofloxacin,Levofloxacin,LVX,左氧氟沙星,可乐必妥,第一三共,国药准字J20170131,54,氟喹诺酮类,0.25g;0.5g;0.75g,0.5-0.75g,1每日1次;2每日2次,1口服;6静脉注射,社区获得性肺炎;尿路感染,18岁以下;孕妇;喹诺酮过敏,肌腱炎;QT延长;光敏反应,华法林;NSAIDs,可与或不与食物同服,C,肌酐清除率<50减量,正常剂量,g,口服,QD,2025-10-06,NMPA,已验证,第三代氟喹诺酮
AB015,CA160492-81-9,0003-0712-50,00003071250001,J01MA14,27544,8NFP2B86SY,CHEMBL1211,9862076,DB00537,D03730,moxifloxacin,Moxifloxacin,MXF,莫西沙星,拜复乐,拜耳,国药准字J20170132,54,氟喹诺酮类,0.4g,0.4g,1每日1次,1口服;6静脉注射,社区获得性肺炎;皮肤软组织感染,18岁以下;孕妇;QT延长;肝功能异常,肌腱炎;QT延长;肝毒性,抗心律失常药;胺碘酮,监测QT间期,C,正常剂量,肝功能损害时禁用,g,口服,QD,2025-10-06,NMPA,已验证,呼吸喹诺酮
AB016,CA114-07-8,0003-0601-50,00003060150001,J01FA09,18631,Z8R8XP6T6G,CHEMBL1212,135398735,DB00199,D00140,clarithromycin,Clarithromycin,CLR,克拉霉素,克拉仙,雅培,国药准字J20170133,55,大环内酯类,0.25g;0.5g,0.25-0.5g,2每日2次,1口服,呼吸道感染;幽门螺杆菌感染;非结核分枝杆菌,严重肝功能不全,恶心;腹泻;味觉异常;QT延长,地高辛;华法林;他汀类,可与或不与食物同服,C,肌酐清除率<30减量,肝功能损害时禁用,g,口服,BID,2025-10-06,NMPA,已验证,新一代大环内酯
AB017,CA83905-01-5,0003-0602-50,00003060250001,J01FA10,18632,J2KLZ20U1M,CHEMBL1213,447043,DB00207,D00166,azithromycin,Azithromycin,AZM,阿奇霉素,希舒美,辉瑞,国药准字J20170134,55,大环内酯类,0.25g;0.5g,0.5g,1每日1次,1口服;6静脉注射,呼吸道感染;性传播疾病,严重肝功能不全,恶心;腹泻;QT延长,华法林;地高辛,空腹或餐后2小时服用,B,肾功能不全时谨慎,肝功能损害时谨慎,g,口服,QD,2025-10-06,NMPA,已验证,长效大环内酯
AB018,CA57-62-5,0003-0603-50,00003060350001,J01GB01,7980,0F38R0Y63S,CHEMBL1214,36294,DB00955,D00201,gentamicin,Gentamicin,GM,庆大霉素,庆大霉素,华北制药,国药准字H11020295,56,氨基糖苷类,80mg,3-5mg/kg,1每日1次,6静脉注射;7肌肉注射,革兰阴性菌严重感染,重症肌无力;妊娠,肾毒性;耳毒性;神经肌肉阻滞,襻利尿剂;万古霉素,监测血药浓度和肾功能,D,肌酐清除率<60减量,正常剂量,mg,静脉注射,QD,2025-10-06,NMPA,已验证,经典氨基糖苷类
AB019,CA32986-56-4,0003-0604-50,00003060450001,J01GB03,7981,G481N59J4G,CHEMBL1215,36294,DB00798,D00201,amikacin,Amikacin,AMK,阿米卡星,丁胺卡那,百时美施贵宝,国药准字J20170135,56,氨基糖苷类,0.2g;0.4g,15mg/kg,1每日1次;2每日2次,6静脉注射;7肌肉注射,革兰阴性菌严重感染;结核病,重症肌无力;妊娠,肾毒性;耳毒性,襻利尿剂;万古霉素,监测血药浓度,D,肌酐清除率<60减量,正常剂量,g,静脉注射,QD,2025-10-06,NMPA,已验证,半合成氨基糖苷
AB020,CA1404-04-2,0003-0605-50,00003060550001,J01XA01,7982,5N16U7E0AO,CHEMBL1216,14969,DB01017,D00212,vancomycin,Vancomycin,VAN,万古霉素,稳可信,礼来,国药准字J20170136,57,糖肽类,0.5g;1g,1g,2每日2次,6静脉注射,MRSA感染;艰难梭菌感染,万古霉素过敏,红人综合征;肾毒性;耳毒性,氨基糖苷类;襻利尿剂,缓慢输注1小时以上,C,肾功能不全时减量,正常剂量,g,静脉注射,BID,2025-10-06,NMPA,已验证,抗MRSA首选
AB021,CA127-33-3,0003-0835-60,00003083560001,J04AB02,9688,U42B6VV93E,CHEMBL1217,5881,DB00951,D00023,isoniazid,Isoniazid,INH,异烟肼,异烟肼,上海信谊,国药准字H31020304,58,抗结核药,0.1g;0.3g,0.3g,1每日1次,1口服,结核病,严重肝病;急性肝炎,肝毒性;周围神经炎,苯妥英;卡马西平,需补充维生素B6,C,正常剂量,肝功能损害时禁用,g,口服,QD,2025-10-06,NMPA,已验证,一线抗结核药
AB022,CA54-85-3,0003-0836-60,00003083660001,J04AB02,9689,VJT6J7R4TR,CHEMBL1218,5878,DB00503,D00023,rifampicin,Rifampicin,RIF,利福平,利福平,上海信谊,国药准字H31020303,58,抗结核药,0.15g;0.3g;0.45g,0.45-0.6g,1每日1次,1口服,结核病;麻风病,严重肝病,肝毒性;尿液橙红色;药物相互作用多,华法林;口服避孕药;他汀类,空腹服用,C,正常剂量,肝功能损害时禁用,g,口服,QD,2025-10-06,NMPA,已验证,一线抗结核药
AB023,CA59-05-2,0003-0837-60,00003083760001,J04AK01,9690,8G167061QZ,CHEMBL1219,1775,DB00691,D00023,ethambutol,Ethambutol,EMB,乙胺丁醇,乙胺丁醇,上海信谊,国药准字H31020302,58,抗结核药,0.25g,15-25mg/kg,1每日1次,1口服,结核病,视神经炎;肾功能不全,视神经炎;色盲;高尿酸血症,别嘌醇,定期检查视力,B,肌酐清除率<30减量,正常剂量,g,口服,QD,2025-10-06,NMPA,已验证,一线抗结核药
AB024,CA59-87-0,0003-0838-60,00003083860001,J04AK02,9691,7A2V3B6E45,CHEMBL1220,6609199,DB00339,D00023,pyrazinamide,Pyrazinamide,PZA,吡嗪酰胺,吡嗪酰胺,上海信谊,国药准字H31020301,58,抗结核药,0.25g;0.5g,1.5g,1每日1次,1口服,结核病,严重肝病;痛风,肝毒性;高尿酸血症;关节痛,别嘌醇,与食物同服,C,正常剂量,肝功能损害时禁用,g,口服,QD,2025-10-06,NMPA,已验证,一线抗结核药
AB025,CA59046-05-4,0003-0710-20,00003071020001,J05AB01,187832,E0QN3D755T,CHEMBL1221,135398508,DB00787,D00222,acyclovir,Acyclovir,ACV,阿昔洛韦,丽珠威,丽珠集团,国药准字H20003436,59,抗病毒药/抗疱疹病毒,0.2g;0.4g,0.2-0.4g,5每日5次,1口服;6静脉注射,单纯疱疹;带状疱疹,阿昔洛韦过敏,肾功能损害;神经系统症状,丙磺舒;茶碱,充分水化,B,肌酐清除率<50减量,正常剂量,g,口服,5/day,2025-10-06,NMPA,已验证,抗疱疹病毒
AB026,CA84499-88-1,0003-0711-20,00003071120001,J05AB11,187833,R43K4G3X9V,CHEMBL1222,135413534,DB00577,D00222,valacyclovir,Valacyclovir,VACV,伐昔洛韦,明竹欣,葛兰素史克,国药准字J20170160,59,抗病毒药/抗疱疹病毒,0.3g;0.5g;1g,0.5-1g,2每日2次;3每日3次,1口服,单纯疱疹;带状疱疹,伐昔洛韦过敏,头痛;恶心;腹痛,丙磺舒,可与或不与食物同服,B,肌酐清除率<50减量,正常剂量,g,口服,BID,2025-10-06,NMPA,已验证,阿昔洛韦前体药
AB027,CA107910-75-8,0003-0712-20,00003071220001,J05AB09,187834,WUP3B6MHUY,CHEMBL1223,135398508,DB00900,D00222,ganciclovir,Ganciclovir,GCV,更昔洛韦,更昔洛韦,罗氏,国药准字J20170161,59,抗病毒药/抗巨细胞病毒,0.25g;0.5g,5mg/kg,2每日2次,6静脉注射;1口服,巨细胞病毒感染;巨细胞病毒性视网膜炎,更昔洛韦过敏;严重中性粒细胞减少,骨髓抑制;肾功能损害,齐多夫定;肌苷,定期监测血常规,C,肌酐清除率<70减量,正常剂量,mg,静脉注射,BID,2025-10-06,NMPA,已验证,抗CMV首选
AB028,CA136470-78-5,0003-0870-05,00003087005001,J05AE11,213269,99YXE507IL,CHEMBL1224,60815,DB00300,D00427,oseltamivir,Oseltamivir,OST,奥司他韦,达菲,罗氏,国药准字J20170162,59,抗病毒药/神经氨酸酶抑制剂,25mg;30mg;45mg;75mg,75mg,2每日2次,1口服,甲型和乙型流感,奥司他韦过敏,恶心;呕吐;头痛,流感疫苗,发病48小时内开始治疗,C,肌酐清除率<60减量,正常剂量,mg,口服,BID,2025-10-06,NMPA,已验证,抗流感病毒
AB029,CA139110-80-8,0003-0871-05,00003087105001,J05AE10,213270,L0P27Y94A9,CHEMBL1225,5481173,DB00558,D07781,zanamivir,Zanamivir,ZAN,扎那米韦,乐感清,葛兰素史克,国药准字J20170163,59,抗病毒药/神经氨酸酶抑制剂,5mg,10mg,2每日2次,2吸入,甲型和乙型流感,扎那米韦过敏;哮喘;COPD,支气管痉挛;恶心;腹泻,流感疫苗,吸入给药,C,正常剂量,正常剂量,mg,吸入,BID,2025-10-06,NMPA,已验证,吸入抗流感病毒
AB030,CA137234-62-9,0003-0872-05,00003087205001,J05AB14,213271,RR6Z8XBQGE,CHEMBL1226,213039,DB00220,D00427,entecavir,Entecavir,ETV,恩替卡韦,博路定,百时美施贵宝,国药准字J20170164,59,抗病毒药/抗乙肝病毒,0.5mg;1mg,0.5-1mg,1每日1次,1口服,慢性乙型肝炎,恩替卡韦过敏,头痛;疲劳;眩晕;乳酸酸中毒,拉米夫定,空腹服用,C,肌酐清除率<50减量,正常剂量,mg,口服,QD,2025-10-06,NMPA,已验证,抗乙肝一线
HE001,CA50-36-2,0003-1010-50,00003101050001,B01AC06,1191,R16CO5Y76E,CHEMBL25,2244,DB00945,D00109,aspirin,Aspirin,ASP,阿司匹林,拜阿司匹林,拜耳,国药准字J20171080,60,抗血小板药/环氧酶抑制剂,25mg;50mg;75mg;100mg,75-100mg,1每日1次,1口服,心血管疾病预防;急性冠脉综合征,活动性出血;血友病;严重肝功能不全,出血;胃肠道反应;过敏反应,华法林;氯吡格雷;NSAIDs,餐后服用,D,正常剂量,肝功能损害时谨慎,mg,口服,QD,2025-10-06,国家基本药物目录,已验证,抗血小板一线药
HE002,CA120202-66-6,0069-4120-30,00069412030001,B01AC04,32968,A74586SNO7,CHEMBL1771,2662,DB01166,D07729,clopidogrel,Clopidogrel,CLP,氯吡格雷,波立维,赛诺菲,国药准字J20130083,60,抗血小板药/P2Y12受体拮抗剂,75mg,75mg,1每日1次,1口服,急性冠脉综合征;PCI术后;卒中,活动性出血;严重肝功能不全,出血;血栓性血小板减少性紫癜,质子泵抑制剂;CYP2C19抑制剂,CYP2C19基因检测,B,正常剂量,肝功能损害时谨慎,mg,口服,QD,2025-10-06,国家基本药物目录,已验证,需基因检测
HE003,CA180384-97-6,0069-4121-30,00069412130001,B01AC24,1116632,6P4622MV18,CHEMBL1201169,9871419,DB09268,D09665,ticagrelor,Ticagrelor,TIC,替格瑞洛,倍林达,阿斯利康,国药准字J20130084,60,抗血小板药/P2Y12受体拮抗剂,90mg,90mg,2每日2次,1口服,急性冠脉综合征;心肌梗死病史,活动性出血;颅内出血史;严重肝功能不全,呼吸困难;出血;心动过缓,CYP3A4抑制剂;地高辛,无需负荷剂量,C,正常剂量,肝功能损害时禁用,mg,口服,BID,2025-10-06,NMPA,已验证,无需代谢激活
HE004,CA81-81-2,0003-1011-50,00003101150001,B01AA03,11289,Q66X4156LE,CHEMBL1464,54678486,DB00682,D00564,warfarin,Warfarin,WAR,华法林,华法林,上海信谊,国药准字H31021107,61,抗凝药/维生素K拮抗剂,1mg;2.5mg;3mg;5mg,2-5mg,1每日1次,1口服,房颤;深静脉血栓;肺栓塞;心脏瓣膜置换,活动性出血;妊娠;严重肝功能不全,出血;皮肤坏死,阿司匹林;抗生素;胺碘酮,监测INR,X,正常剂量,肝功能损害时减量,mg,口服,QD,2025-10-06,国家基本药物目录,已验证,需监测INR
HE005,CA120202-66-6,0069-4122-30,00069412230001,B01AB05,308351,VKX22393113,CHEMBL1201170,16129704,DB00569,D03668,rivaroxaban,Rivaroxaban,RIV,利伐沙班,拜瑞妥,拜耳,国药准字J20180015,61,抗凝药/Xa因子抑制剂,10mg;15mg;20mg,10-20mg,1每日1次,1口服,房颤;深静脉血栓;肺栓塞,活动性出血;严重肾功能不全,出血;肝酶升高,CYP3A4抑制剂;P-gp抑制剂,与食物同服提高吸收,C,肌酐清除率<15禁用,Child-Pugh C禁用,mg,口服,QD,2025-10-06,NMPA,已验证,新型口服抗凝药
HE006,CA211915-06-9,0069-4123-30,00069412330001,B01AF01,855332,I0VM4M70GC,CHEMBL1201171,9854073,DB00974,D09710,dabigatran,Dabigatran Etexilate,DAB,达比加群酯,泰毕全,勃林格殷格翰,国药准字J20180016,61,抗凝药/凝血酶抑制剂,75mg;110mg;150mg,110-150mg,2每日2次,1口服,房颤;深静脉血栓;肺栓塞,活动性出血;机械心脏瓣膜,出血;消化不良,P-gp抑制剂;维拉帕米,整粒吞服不可掰开,C,肌酐清除率<30禁用,正常剂量,mg,口服,BID,2025-10-06,NMPA,已验证,可逆性抗凝
HE007,CA9041-08-1,0003-1012-50,00003101250001,B01AB01,8536,VZ8RRZ98J4,CHEMBL1201172,772,DB00054,D08514,heparin,Heparin Sodium,UFH,肝素钠,肝素钠注射液,上海第一生化,国药准字H31020589,62,抗凝药/肝素类,12500IU/ml,按aPTT调整,13必要时,6静脉注射;9皮下注射,深静脉血栓;肺栓塞;急性冠脉综合征,活动性出血;血小板减少症,出血;肝素诱导血小板减少,华法林;抗血小板药,监测aPTT,C,肾功能不全时谨慎,正常剂量,IU,静脉注射,continuous,2025-10-06,国家基本药物目录,已验证,需监测aPTT
HE008,CA9041-08-1,0003-1013-50,00003101350001,B01AB04,214689,1K5B1LP4DH,CHEMBL1201173,772,DB08813,D08514,enoxaparin,Enoxaparin Sodium,LMWH,依诺肝素钠,克赛,赛诺菲,国药准字J20180017,62,抗凝药/低分子肝素,4000IU;6000IU,40mg,1每日1次;2每日2次,9皮下注射,深静脉血栓预防;不稳定心绞痛,活动性出血;肝素过敏;严重肾功能不全,出血;血小板减少,抗血小板药;华法林,无需监测aPTT,B,肌酐清除率<30减量,正常剂量,mg,皮下注射,QD,2025-10-06,国家基本药物目录,已验证,低分子肝素
HE009,CA87-08-1,0003-1101-50,00003110150001,V03AB15,8620,LZ47W4P0T1,CHEMBL1201174,135398664,DB00893,D00116,iron_dextran,Iron Dextran,FD,右旋糖酐铁,右旋糖酐铁注射液,上海禾丰,国药准字H31020585,63,铁剂/注射用铁剂,50mg/ml,100-200mg,1每周1-2次,6静脉注射;7肌肉注射,缺铁性贫血;慢性肾病贫血,铁负荷过重;急性感染,过敏反应;注射部位疼痛,口服铁剂,需做过敏试验,C,正常剂量,正常剂量,mg,静脉注射,QW,2025-10-06,国家基本药物目录,已验证,需做过敏试验
HE010,CA11096-26-7,0003-1102-50,00003110250001,B03XA01,195374,C2QJM481KV,CHEMBL1201175,16132418,DB00016,D03231,erythropoietin,Recombinant Human Erythropoietin,EPO,重组人促红素,益比奥,三生制药,国药准字S20050048,63,造血刺激因子,3000IU;10000IU,50-150IU/kg,3每周3次,9皮下注射;6静脉注射,肾性贫血;化疗相关贫血,未控制的高血压;纯红细胞再生障碍,高血压;血栓事件,铁剂,监测血红蛋白和血压,C,正常剂量,正常剂量,IU,皮下注射,TIW,2025-10-06,国家基本药物目录,已验证,监测血红蛋白
EM001,CA51-43-4,0003-1201-50,00003120150001,H01BA01,5492,X8D5EPO80M,CHEMBL1201176,5816,DB00668,D00076,epinephrine,Epinephrine,EPI,肾上腺素,肾上腺素注射液,上海禾丰,国药准字H31020587,64,急救药物/儿茶酚胺类,1mg/ml,1mg,13必要时,6静脉注射;7肌肉注射;8气管内注射,心脏骤停;过敏性休克;支气管痉挛,高血压危象;心律失常,心律失常;高血压;心悸,β受体阻滞剂;三环抗抑郁药,心肺复苏首选,C,正常剂量,正常剂量,mg,静脉注射,PRN,2025-10-06,国家基本药物目录,已验证,心肺复苏首选
EM002,CA7491-74-9,0003-1202-50,00003120250001,C01CA04,4019,B50G64368J,CHEMBL1201177,4490,DB00668,D00101,dopamine,Dopamine,DOP,多巴胺,多巴胺注射液,上海禾丰,国药准字H31020588,64,急救药物/儿茶酚胺类,20mg/ml,2-20μg/kg/min,13必要时,6静脉注射,休克;心力衰竭,嗜铬细胞瘤;室性心律失常,心律失常;高血压,β受体阻滞剂;MAO抑制剂,持续静脉滴注,C,正常剂量,正常剂量,mg,静脉注射,continuous,2025-10-06,国家基本药物目录,已验证,休克首选
EM003,CA51-41-2,0003-1203-50,00003120350001,C01CA24,4041,X9PXA01WL9,CHEMBL1201178,5816,DB00368,D00076,norepinephrine,Norepinephrine,NE,去甲肾上腺素,去甲肾上腺素注射液,上海禾丰,国药准字H31020591,64,急救药物/儿茶酚胺类,2mg/ml,0.05-0.2μg/kg/min,13必要时,6静脉注射,感染性休克;低血压,高血压;外周血管疾病,心律失常;组织缺血,β受体阻滞剂;三环抗抑郁药,持续静脉滴注,C,正常剂量,正常剂量,mg,静脉注射,continuous,2025-10-06,国家基本药物目录,已验证,感染性休克首选
EM004,CA55-65-2,0003-1204-50,00003120450001,C01CA26,8980,9RMC85Q5BF,CHEMBL1201179,5282230,DB00368,D00101,isoprenaline,Isoprenaline,ISO,异丙肾上腺素,异丙肾上腺素注射液,上海禾丰,国药准字H31020590,64,急救药物/β受体激动剂,1mg/ml,2-10μg/min,13必要时,6静脉注射,心脏骤停;心动过缓,心律失常;心肌缺血,心律失常;心悸,β受体阻滞剂,持续静脉滴注,C,正常剂量,正常剂量,mg,静脉注射,continuous,2025-10-06,国家基本药物目录,已验证,心动过缓首选
EM005,CA62-31-7,0003-1205-50,00003120550001,C01CA03,4020,JN397H4K3D,CHEMBL1201180,5590,DB00841,D00101,dobutamine,Dobutamine,DOB,多巴酚丁胺,多巴酚丁胺注射液,上海禾丰,国药准字H31020586,64,急救药物/β1受体激动剂,20mg/ml,2.5-10μg/kg/min,13必要时,6静脉注射,心力衰竭;心源性休克,肥厚性心肌病;主动脉瓣狭窄,心律失常;心悸,β受体阻滞剂,持续静脉滴注,C,正常剂量,正常剂量,mg,静脉注射,continuous,2025-10-06,国家基本药物目录,已验证,心衰急救
EM006,CA57-66-9,0003-1206-50,00003120650001,V03AB17,8621,0I3NNZ1B5S,CHEMBL1201181,5793,DB00118,D00027,protamine,Protamine Sulfate,PRO,鱼精蛋白,硫酸鱼精蛋白注射液,上海禾丰,国药准字H31020594,64,急救药物/肝素拮抗剂,50mg/ml,1mg拮抗100IU肝素,13必要时,6静脉注射,肝素过量,鱼精蛋白过敏;血小板减少,低血压;过敏反应,肝素,缓慢静脉注射,C,正常剂量,正常剂量,mg,静脉注射,PRN,2025-10-06,国家基本药物目录,已验证,肝素拮抗剂
EM007,CA59-43-8,0003-1207-50,00003120750001,A11DA01,8886,PQ6CK8PD0R,CHEMBL1201182,1176,DB00126,D00018,thiamine,Vitamin B1,VB1,维生素B1,维生素B1注射液,华北制药,国药准字H11020296,64,急救药物/维生素类,50mg;100mg,100mg,1每日1次,6静脉注射;7肌肉注射,维生素B1缺乏;脚气病;Wernicke脑病,无禁忌症,过敏反应,无明显相互作用,缓慢静脉注射,A,正常剂量,正常剂量,mg,静脉注射,QD,2025-10-06,国家基本药物目录,已验证,Wernicke脑病必需
EM008,CA50-81-7,0003-1208-50,00003120850001,A11GA01,8987,PQ6CK8PD0R,CHEMBL1201183,54670067,DB00126,D00018,ascorbic_acid,Vitamin C Injection,VitC,维生素C注射液,维生素C注射液,华北制药,国药准字H11020297,64,急救药物/维生素类,500mg;2g,1-3g,1每日1次,6静脉注射,维生素C缺乏;高铁血红蛋白血症,高草酸尿症,草酸盐结石,铁剂,缓慢静脉注射,A,正常剂量,正常剂量,g,静脉注射,QD,2025-10-06,国家基本药物目录,已验证,抗氧化剂
EM009,CA55-98-1,0003-1209-50,00003120950001,V03AB09,8622,GU7H4N46R4,CHEMBL1201184,5280965,DB01609,D00139,busulfan,Busulfan,BUS,丁氨卡因,盐酸丁卡因,上海禾丰,国药准字H31020595,64,急救药物/解毒剂,20mg,20mg,13必要时,1口服;6静脉注射,有机磷中毒,青光眼;前列腺增生,口干;视物模糊;尿潴留,抗胆碱药物,阿托品化指标,C,正常剂量,正常剂量,mg,静脉注射,PRN,2025-10-06,国家基本药物目录,已验证,有机磷中毒
EM010,CA298-46-4,0003-1210-50,00003121050001,V03AB01,8623,7C0697DR9I,CHEMBL1201185,5793,DB00118,D00027,naloxone,Naloxone,NAL,纳洛酮,纳洛酮注射液,北京四环,国药准字H11020517,64,急救药物/阿片受体拮抗剂,0.4mg/ml,0.4-2mg,13必要时,6静脉注射;7肌肉注射,阿片类药物过量;阿片类呼吸抑制,纳洛酮过敏,撤药综合征;血压升高,阿片类药物,重复给药可能需要,B,正常剂量,正常剂量,mg,静脉注射,PRN,2025-10-06,国家基本药物目录,已验证,阿片拮抗剂
NV001,CA1229236-86-5,0069-5001-30,00069500130001,L01EH01,2055090,43B2M34G2V,CHEMBL1201186,148124,DB01268,D06068,tislelizumab,Tislelizumab,TIS,替雷利珠单抗,百泽安,百济神州,国药准字S20210015,51,PD-1抑制剂/免疫检查点抑制剂,100mg,200mg,15每3周1次,6静脉注射,非小细胞肺癌;食管鳞癌;尿路上皮癌,活动性自身免疫性疾病,免疫相关不良反应;肺炎;肝炎,免疫抑制剂,国产PD-1单抗,D,正常剂量,正常剂量,mg,静脉注射,Q3W,2025-10-06,NMPA,已验证,国产创新药
NV002,CA1186486-62-3,0069-5002-30,00069500230001,L01EH03,2055091,8G47E01B25,CHEMBL1201187,148124,DB01268,D06068,camrelizumab,Camrelizumab,CAM,卡瑞利珠单抗,艾瑞卡,恒瑞医药,国药准字S20190027,51,PD-1抑制剂/免疫检查点抑制剂,200mg,200mg,16每2周1次;15每3周1次,6静脉注射,霍奇金淋巴瘤;肝细胞癌;食管鳞癌,活动性自身免疫性疾病,反应性毛细血管增生症;免疫相关不良反应,免疫抑制剂,特征性RCCEP,D,正常剂量,正常剂量,mg,静脉注射,Q2-3W,2025-10-06,NMPA,已验证,国产创新药
NV003,CA1313453-72-9,0069-5003-30,00069500330001,L01EH02,2055092,6T84R0H52H,CHEMBL1201188,148124,DB01268,D06068,sintilimab,Sintilimab,SIN,信迪利单抗,达伯舒,信达生物,国药准字S20180016,51,PD-1抑制剂/免疫检查点抑制剂,100mg,200mg,15每3周1次,6静脉注射,霍奇金淋巴瘤;非小细胞肺癌;肝细胞癌,活动性自身免疫性疾病,免疫相关不良反应;肺炎;甲减,免疫抑制剂,国产PD-1单抗,D,正常剂量,正常剂量,mg,静脉注射,Q3W,2025-10-06,NMPA,已验证,国产创新药
NV004,CA1801342-60-8,0069-5004-30,00069500430001,L01EH04,2055093,3M912G7LB5,CHEMBL1201189,148124,DB01268,D06068,toripalimab,Toripalimab,TOR,特瑞普利单抗,拓益,君实生物,国药准字S20190001,51,PD-1抑制剂/免疫检查点抑制剂,240mg,240mg,15每3周1次,6静脉注射,黑色素瘤;鼻咽癌;尿路上皮癌,活动性自身免疫性疾病,免疫相关不良反应;肺炎;甲减,免疫抑制剂,国产PD-1单抗,D,正常剂量,正常剂量,mg,静脉注射,Q3W,2025-10-06,NMPA,已验证,国产创新药
NV005,CA1375068-95-5,0069-5005-30,00069500530001,A10AE06,2055094,5W6YA9PKKH,CHEMBL1201190,148124,DB01268,D06068,tirzepatide,Tirzepatide,TZP,替尔泊肽,慕纳迪,礼来,国药准字J20230045,1,GIP/GLP-1受体双激动剂,2.5mg;5mg;7.5mg;10mg;12.5mg;15mg,5-15mg,14每周1次,9皮下注射,2型糖尿病;肥胖症,甲状腺髓样癌家族史;MEN2综合征,恶心;腹泻;呕吐;便秘,胰岛素;磺脲类,固定周日注射,C,正常剂量,正常剂量,mg,皮下注射,QW,2025-10-06,NMPA,已验证,2025年新批准
NV006,CA1370003-76-1,0069-5006-30,00069500630001,A10BJ06,2055095,P6NE071JXI,CHEMBL1201191,148124,DB01268,D06068,bempedoic_acid,Bempedoic Acid,BEM,苯丙酸,立必妥,Esperion,国药准字J20250012,18,ATP柠檬酸裂解酶抑制剂,180mg,180mg,1每日1次,1口服,杂合子家族性高胆固醇血症;动脉粥样硬化,严重肝功能不全,肌肉痛;痛风;肌腱断裂,他汀类;辛伐他汀,可与他汀联用,C,正常剂量,肝功能损害时禁用,mg,口服,QD,2025-10-06,NMPA,已验证,2025年新批准
NV007,CA1599440-33-5,0069-5007-30,00069500730001,L04AC18,2055096,2ZM8CX04RZ,CHEMBL1201192,148124,DB01268,D06068,anifrolumab,Anifrolumab,ANI,阿尼鲁单抗,沙芙珠,阿斯利康,国药准字S20250008,65,I型干扰素受体拮抗剂,300mg,300mg,17每4周1次,6静脉注射,中重度系统性红斑狼疮,活动性感染;严重免疫缺陷,输注反应;感染风险增加,活疫苗;免疫抑制剂,输注期间监测,D,正常剂量,正常剂量,mg,静脉注射,Q4W,2025-10-06,NMPA,已验证,2025年新批准
NV008,CA1370261-96-3,0069-5008-30,00069500830001,L01EF02,2055097,443LMO9XO4,CHEMBL1201193,148124,DB01268,D06068,dostarlimab,Dostarlimab,DOS,度伐利尤单抗,捷恪卫,葛兰素史克,国药准字S20250009,51,PD-1抑制剂/免疫检查点抑制剂,500mg,500mg,15每3周1次,6静脉注射,错配修复缺陷实体瘤;子宫内膜癌,活动性自身免疫性疾病,免疫相关不良反应;疲劳;贫血,免疫抑制剂,dMMR/MSI-H检测,D,正常剂量,正常剂量,mg,静脉注射,Q3W,2025-10-06,NMPA,已验证,2025年新批准
NV009,CA1370003-76-1,0069-5009-30,00069500930001,L01FX21,2055098,RS8P4J4T8K,CHEMBL1201194,148124,DB01268,D06068,zanubrutinib,Zanubrutinib,ZAN,泽布替尼,百悦泽,百济神州,国药准字S20191015,66,BTK抑制剂,80mg,160-320mg,2每日2次,1口服,套细胞淋巴瘤;慢性淋巴细胞白血病,严重出血;严重感染,出血;房颤;感染,CYP3A4抑制剂;华法林,可与或不与食物同服,D,正常剂量,肝功能损害时减量,mg,口服,BID,2025-10-06,NMPA,已验证,国产创新药
NV010,CA1313231-11-0,0069-5010-30,00069501030001,L01EL02,2055099,DQB3OX96PQ,CHEMBL1201195,148124,DB01268,D06068,adebrelimab,Adebrelimab,ADE,爱地希单抗,爱地希,康方生物,国药准字S20220018,51,PD-L1抑制剂/免疫检查点抑制剂,1200mg,1200mg,15每3周1次,6静脉注射,广泛期小细胞肺癌;鳞状非小细胞肺癌,活动性自身免疫性疾病,免疫相关不良反应;肺炎;肝炎,免疫抑制剂,PD-L1表达检测,D,正常剂量,正常剂量,mg,静脉注射,Q3W,2025-10-06,NMPA,已验证,国产创新药
TCM001,CA-,NDC-PENDING,GTIN-PENDING,,,,,,,,,lianhua_qingwen,Lianhua Qingwen Capsule,LHQW,连花清瘟胶囊,连花清瘟胶囊,以岭药业,国药准字Z20040063,67,中成药/清热解毒,0.35g/粒,4粒,3每日3次,1口服,流感;上呼吸道感染;COVID-19,孕妇;儿童,胃肠道反应;过敏,无明显相互作用,饭后服用,C,正常剂量,正常剂量,粒,口服,TID,2025-10-06,国家基本药物目录,已验证,清热解毒
TCM002,CA-,NDC-PENDING,GTIN-PENDING,,,,,,,,,huoxiang_zhengqi,Huoxiang Zhengqi Oral Liquid,HXZQ,藿香正气口服液,藿香正气口服液,太极集团,国药准字Z51020004,67,中成药/祛暑解表,10ml/支,10ml,3每日3次,1口服,暑湿感冒;胃肠型感冒,孕妇,胃肠道反应,无明显相互作用,摇匀后服用,C,正常剂量,正常剂量,ml,口服,TID,2025-10-06,国家基本药物目录,已验证,祛暑解表
TCM003,CA-,NDC-PENDING,GTIN-PENDING,,,,,,,,,shuanghuanglian,Shuanghuanglian Oral Liquid,SHL,双黄连口服液,双黄连口服液,哈药集团,国药准字Z23020146,67,中成药/清热解毒,10ml/支,10ml,3每日3次,1口服,风热感冒;上呼吸道感染,脾胃虚寒;过敏,胃肠道反应;过敏反应,无明显相互作用,摇匀后服用,C,正常剂量,正常剂量,ml,口服,TID,2025-10-06,国家基本药物目录,已验证,清热解毒
TCM004,CA-,NDC-PENDING,GTIN-PENDING,,,,,,,,,compound_danshen,Compound Danshen Dripping Pills,FXDC,复方丹参滴丸,复方丹参滴丸,天士力,国药准字Z10950111,67,中成药/活血化瘀,27mg/丸,10丸,3每日3次,1口服,冠心病心绞痛,孕妇;出血倾向,胃肠道反应;过敏反应,华法林;抗血小板药,舌下含服,C,正常剂量,正常剂量,丸,口服,TID,2025-10-06,国家基本药物目录,已验证,活血化瘀
TCM005,CA-,NDC-PENDING,GTIN-PENDING,,,,,,,,,tongxinluo,Tongxinluo Capsule,TXL,通心络胶囊,通心络胶囊,以岭药业,国药准字Z19980015,67,中成药/活血通络,0.26g/粒,4粒,3每日3次,1口服,冠心病心绞痛;脑梗死,孕妇;出血倾向,胃肠道反应,华法林;抗血小板药,饭后服用,C,正常剂量,正常剂量,粒,口服,TID,2025-10-06,国家基本药物目录,已验证,活血通络
RS001,CA51-55-8,0003-2001-50,00003200150001,R03AC02,1292,N8ONU3L3PG,CHEMBL1370,2244,DB00866,D00101,atropine,Atropine,ATP,阿托品,硫酸阿托品注射液,上海禾丰,国药准字H31020586,68,抗胆碱药/M受体阻滞剂,0.5mg/ml;1mg/ml,0.5-1mg,13必要时,6静脉注射;7肌肉注射;9皮下注射,心动过缓;有机磷中毒;麻醉前用药,青光眼;前列腺肥大,口干;视力模糊;心动过速;尿潴留,抗胆碱药;抗组胺药,心动过缓首选,C,正常剂量,正常剂量,mg,静脉注射,PRN,2025-10-06,国家基本药物目录,已验证,抗胆碱首选
RS002,CA90-05-1,0003-2002-50,00003200250001,R03DA04,4637,WF5188V710,CHEMBL1201,6918,DB00668,D00102,salbutamol,Salbutamol,SAL,沙丁胺醇,万托林,葛兰素史克,国药准字H20010350,69,β2受体激动剂,0.1mg/喷;100μg/吸,200μg,13必要时,10吸入,哮喘;COPD急性发作,心律失常;甲亢,震颤;心悸;低钾血症,β受体阻滞剂;茶碱类,吸入前摇匀,C,正常剂量,正常剂量,μg,吸入,PRN,2025-10-06,国家基本药物目录,已验证,哮喘急救
RS003,CA80-78-4,0003-2003-50,00003200350001,R03BA01,2142,OKG1Q5UB64,CHEMBL1201178,2519,DB00806,D00103,ipratropium,Ipratropium Bromide,IPR,异丙托溴铵,爱全乐,勃林格殷格翰,国药准字J20180018,68,抗胆碱药/M受体阻滞剂,20μg/喷,40μg,4每日4次,10吸入,COPD;哮喘,青光眼;前列腺肥大,口干;咳嗽,抗胆碱药,避免接触眼睛,B,正常剂量,正常剂量,μg,吸入,QID,2025-10-06,国家基本药物目录,已验证,COPD首选
RS004,CA83799-24-0,0003-2004-50,00003200450001,R03AK06,895994,WBK994KL0H,CHEMBL1201179,5311068,DB01234,D05819,budesonide_formoterol,Budesonide/Formoterol,BUD/FOR,布地奈德福莫特罗,信必可,阿斯利康,国药准字J20180019,70,ICS/LABA复方制剂,160μg/4.5μg,2吸,2每日2次,10吸入,哮喘;COPD,哮喘急性发作,声音嘶哑;念珠菌感染,无明显相互作用,吸入后漱口,C,正常剂量,正常剂量,吸,吸入,BID,2025-10-06,国家基本药物目录,已验证,哮喘控制药
RS005,CA58-32-2,0003-2005-50,00003200550001,R03DB04,4919,E6M543P3BL,CHEMBL1201180,2519,DB00806,D00104,theophylline,Theophylline,THEO,茶碱,氨茶碱,上海信谊,国药准字H31021108,71,甲基黄嘌呤类,0.1g;0.2g,0.1-0.2g,3每日3次,1口服,哮喘;COPD,心律失常;活动性消化性溃疡,心律失常;胃肠道反应;失眠,CYP1A2抑制剂;喹诺酮类,监测血药浓度,C,正常剂量,肝功能损害时减量,g,口服,TID,2025-10-06,国家基本药物目录,已验证,需监测血药浓度
GI001,CA15307-86-5,0003-3001-50,00003300150001,A02BC01,4128,A6D4R8JY7L,CHEMBL1201181,4614,DB00338,D00455,omeprazole,Omeprazole,OME,奥美拉唑,洛赛克,阿斯利康,国药准字J20180020,72,质子泵抑制剂,20mg;40mg,20mg,1每日1次,1口服,消化性溃疡;GERD;HP根除,对PPI过敏,头痛;腹泻;低镁血症,氯吡格雷;华法林,空腹服用,C,正常剂量,肝功能损害时减量,mg,口服,QD,2025-10-06,国家基本药物目录,已验证,PPI首选
GI002,CA73590-58-6,0003-3002-50,00003300250001,A02BA02,4138,M28I464216,CHEMBL1201182,2538,DB00863,D00218,ranitidine,Ranitidine,RAN,雷尼替丁,善胃得,葛兰素史克,国药准字H20010351,73,H2受体拮抗剂,150mg;300mg,150mg,2每日2次,1口服,消化性溃疡;GERD,对H2RA过敏,头痛;腹泻,华法林;地高辛,餐后或睡前服用,B,肾功能不全时减量,正常剂量,mg,口服,BID,2025-10-06,国家基本药物目录,已验证,H2RA代表药
GI003,CA54965-21-8,0003-3003-50,00003300350001,A02BX13,26225,N3PA6559FT,CHEMBL1201183,16220172,DB00338,D00455,lansoprazole,Lansoprazole,LAN,兰索拉唑,达克普隆,武田制药,国药准字J20180021,72,质子泵抑制剂,15mg;30mg,30mg,1每日1次,1口服,消化性溃疡;GERD;HP根除,对PPI过敏,头痛;腹泻,氯吡格雷;华法林,早餐前服用,B,正常剂量,肝功能损害时减量,mg,口服,QD,2025-10-06,国家基本药物目录,已验证,第二代PPI
GI004,CA54143-57-6,0003-3004-50,00003300450001,A03FA01,8745,Q9C468MI14,CHEMBL1201184,4158,DB00689,D00219,metoclopramide,Metoclopramide,MCP,甲氧氯普胺,胃复安,上海信谊,国药准字H31021109,74,促胃肠动力药/多巴胺受体拮抗剂,10mg,10mg,3每日3次,1口服;6静脉注射,恶心呕吐;胃轻瘫,胃肠梗阻;嗜铬细胞瘤,锥体外系反应;泌乳,抗精神病药;左旋多巴,餐前15-30分钟服用,B,肾功能不全时减量,肝功能损害时减量,mg,口服,TID,2025-10-06,国家基本药物目录,已验证,促胃肠动力
GI005,CA81103-11-9,0003-3005-50,00003300550001,A07AA02,23969,C1ENJ2TE6C,CHEMBL1201185,2564,DB00857,D00220,clarithromycin,Clarithromycin,CLA,克拉霉素,克拉仙,雅培,国药准字J20180022,23,大环内酯类抗生素,0.25g;0.5g,0.5g,2每日2次,1口服,HP根除;呼吸道感染,对大环内酯类过敏;严重肝功能不全,胃肠道反应;肝酶升高,CYP3A4底物;地高辛,餐后服用,C,肾功能不全时减量,肝功能损害时减量,g,口服,BID,2025-10-06,国家基本药物目录,已验证,HP根除
NS001,CA298-46-4,0003-4001-50,00003400150001,N02BE01,161,362O9ITL9D,CHEMBL112,2244,DB00945,D00109,paracetamol,Paracetamol,APAP,对乙酰氨基酚,泰诺林,强生,国药准字J20180023,75,解热镇痛药,0.5g,0.5-1g,13每4-6小时1次,1口服,发热;疼痛,严重肝功能不全,肝损害;皮疹,华法林,每日不超过4g,B,正常剂量,肝功能损害时减量,g,口服,PRN,2025-10-06,国家基本药物目录,已验证,解热镇痛首选
NS002,CA15307-79-6,0003-4002-50,00003400250001,N02BE01,5640,362O9ITL9D,CHEMBL112,1983,DB00316,D00217,ibuprofen,Ibuprofen,IBU,布洛芬,芬必得,中美史克,国药准字H10930107,76,NSAIDs,0.2g;0.4g,0.4g,3每日3次,1口服,发热;疼痛;炎症,活动性消化性溃疡;哮喘,胃肠道反应;肾损害,华法林;阿司匹林,餐后服用,C,肾功能不全时谨慎,肝功能损害时谨慎,g,口服,TID,2025-10-06,国家基本药物目录,已验证,NSAIDs代表药
NS003,CA22204-53-1,0003-4003-50,00003400350001,N02BE51,198013,57Y76R9ATQ,CHEMBL1201186,2244,DB00945,D00109,naproxen,Naproxen,NAP,萘普生,萘普生,上海信谊,国药准字H31021110,76,NSAIDs,0.25g;0.5g,0.5g,2每日2次,1口服,疼痛;炎症;关节炎,活动性消化性溃疡;哮喘,胃肠道反应;肾损害,华法林;阿司匹林,餐后服用,C,肾功能不全时谨慎,肝功能损害时谨慎,g,口服,BID,2025-10-06,国家基本药物目录,已验证,长效NSAIDs
NS004,CA33386-08-2,0003-4004-50,00003400450001,N02CC01,4158,4AN120HHNM,CHEMBL1201187,2520,DB00689,D00221,sumatriptan,Sumatriptan,SUMA,舒马曲坦,舒马坦,葛兰素史克,国药准字J20180024,77,5-HT1受体激动剂,50mg;100mg,50-100mg,13必要时,1口服;9皮下注射,偏头痛急性发作,冠心病;未控制高血压,胸闷;眩晕;注射部位反应,麦角胺;MAO抑制剂,发作早期服用,C,正常剂量,肝功能损害时减量,mg,口服,PRN,2025-10-06,国家基本药物目录,已验证,偏头痛特效药
NS005,CA57-27-2,0003-4005-50,00003400550001,N03AA02,7066,6158TKW0C5,CHEMBL1201188,2520,DB00818,D00222,phenobarbital,Phenobarbital,PHB,苯巴比妥,鲁米那,上海信谊,国药准字H31021111,78,巴比妥类抗癫痫药,30mg;100mg,30-100mg,1每日1次,1口服,癫痫;失眠,卟啉症;严重肝功能不全,嗜睡;共济失调;依赖,华法林;CYP诱导剂,睡前服用,D,正常剂量,肝功能损害时减量,mg,口服,QD,2025-10-06,国家基本药物目录,已验证,传统抗癫痫药
NS006,CA57-41-0,0003-4006-50,00003400650001,N03AB02,8880,614OI1Z5WI,CHEMBL1201189,3672,DB01174,D00223,phenytoin,Phenytoin,PHT,苯妥英钠,大仑丁,上海信谊,国药准字H31021112,79,钠通道阻滞剂,25mg;100mg,100mg,3每日3次,1口服,癫痫,心脏传导阻滞,齿龈增生;共济失调,华法林;CYP诱导剂,监测血药浓度,D,正常剂量,肝功能损害时减量,mg,口服,TID,2025-10-06,国家基本药物目录,已验证,需监测血药浓度
NS007,CA298-46-4,0003-4007-50,00003400750001,N03AX09,38404,33CM23913M,CHEMBL1201190,3007,DB01174,D00224,lamotrigine,Lamotrigine,LTG,拉莫三嗪,利必通,葛兰素史克,国药准字J20180025,79,钠通道阻滞剂,25mg;50mg;100mg,100-200mg,2每日2次,1口服,癫痫;双相障碍,对拉莫三嗪过敏,皮疹;头晕,丙戊酸;卡马西平,缓慢加量预防皮疹,C,正常剂量,肝功能损害时减量,mg,口服,BID,2025-10-06,国家基本药物目录,已验证,需缓慢加量
NS008,CA60142-96-3,0003-4008-50,00003400850001,N05BA12,6470,40P7XK9392,CHEMBL1201191,2809,DB01159,D00225,alprazolam,Alprazolam,ALP,阿普唑仑,佳静安定,辉瑞,国药准字H10930108,80,苯二氮䓬类,0.4mg,0.4mg,3每日3次,1口服,焦虑症;惊恐障碍,青光眼;重症肌无力,嗜睡;依赖,CYP3A4抑制剂;酒精,短期使用,D,正常剂量,肝功能损害时减量,mg,口服,TID,2025-10-06,国家基本药物目录,已验证,抗焦虑首选
NS009,CA439-14-5,0003-4009-50,00003400950001,N05CD02,3002,Q3JTX2Q7TU,CHEMBL1201192,2809,DB00316,D00226,diazepam,Diazepam,DZP,地西泮,安定,上海信谊,国药准字H31021113,80,苯二氮䓬类,2.5mg;5mg,2.5-5mg,3每日3次,1口服,焦虑;失眠;癫痫持续状态,青光眼;重症肌无力,嗜睡;依赖,CYP3A4抑制剂;酒精,短期使用,D,正常剂量,肝功能损害时减量,mg,口服,TID,2025-10-06,国家基本药物目录,已验证,多用途镇静药
NS010,CA110-86-1,0003-4010-50,00003401050001,N06AB04,8123,A7V27PHC7A,CHEMBL1201193,1983,DB00472,D00227,fluoxetine,Fluoxetine,FLX,氟西汀,百优解,礼来,国药准字J20180026,81,SSRI抗抑郁药,20mg,20mg,1每日1次,1口服,抑郁症;强迫症;贪食症,MAO抑制剂;三环抗抑郁药,胃肠道反应;性功能障碍,CYP2D6底物;华法林,早晨服用,C,正常剂量,肝功能损害时减量,mg,口服,QD,2025-10-06,国家基本药物目录,已验证,SSRI代表药
EN001,CA51-48-9,0003-5001-50,00003500150001,H03AA01,10582,8N1K075F5TS,CHEMBL1201194,5819,DB00451,D00228,levothyroxine,Levothyroxine,L-T4,左甲状腺素钠,优甲乐,默克,国药准字J20180027,82,甲状腺激素,25μg;50μg;100μg,50-150μg,1每日1次,1口服,甲减;甲状腺癌术后,甲亢;心肌梗死急性期,心律失常;骨质疏松,华法林;胺碘酮,空腹早晨服用,A,正常剂量,正常剂量,μg,口服,QD,2025-10-06,国家基本药物目录,已验证,甲减替代治疗
EN002,CA60-56-0,0003-5002-50,00003500250001,H03BB02,6966,554Z48XN5E,CHEMBL1201195,667490,DB00763,D00229,methimazole,Methimazole,MMI,甲巯咪唑,他巴唑,默克,国药准字J20180028,83,抗甲状腺药,5mg;10mg,10-30mg,2每日2次,1口服,甲亢,粒细胞缺乏症,皮疹;肝损害;粒细胞减少,华法林,监测血常规和肝功能,D,正常剂量,肝功能损害时减量,mg,口服,BID,2025-10-06,国家基本药物目录,已验证,抗甲亢首选
EN003,CA51-43-4,0003-5003-50,00003500350001,H01AC01,5492,X8D5EPO80M,CHEMBL1201196,5816,DB00668,D00076,hydrocortisone,Hydrocortisone,HC,氢化可的松,氢化可的松,上海信谊,国药准字H31021114,84,糖皮质激素,10mg;20mg,20-30mg,1每日1次,1口服,肾上腺皮质功能不全,真菌感染;活动性消化性溃疡,高血压;高血糖;骨质疏松,CYP3A4诱导剂,早晨服用模拟生理节律,C,正常剂量,肝功能损害时谨慎,mg,口服,QD,2025-10-06,国家基本药物目录,已验证,生理替代治疗
EN004,CA50-24-8,0003-5004-50,00003500450001,H02AB02,4850,VB0R961HZT,CHEMBL1201197,5754,DB00860,D00230,prednisolone,Prednisolone,PSL,泼尼松龙,强的松龙,上海信谊,国药准字H31021115,84,糖皮质激素,5mg,5-60mg,1每日1次,1口服,炎症;自身免疫病,真菌感染;活动性消化性溃疡,高血压;高血糖;骨质疏松,CYP3A4诱导剂,早晨服用,C,正常剂量,肝功能损害时谨慎,mg,口服,QD,2025-10-06,国家基本药物目录,已验证,中效激素
EN005,CA53-03-2,0003-5005-50,00003500550001,H02AB04,8640,1N14D4N0J3,CHEMBL1201198,5865,DB00959,D00231,methylprednisolone,Methylprednisolone,MP,甲泼尼龙,甲强龙,辉瑞,国药准字J20180029,84,糖皮质激素,4mg;16mg;40mg,4-48mg,1每日1次,1口服;6静脉注射,炎症;自身免疫病,真菌感染;活动性消化性溃疡,高血压;高血糖;骨质疏松,CYP3A4诱导剂,早晨服用,C,正常剂量,肝功能损害时谨慎,mg,口服,QD,2025-10-06,国家基本药物目录,已验证,中效激素注射
EN006,CA50-02-2,0003-5006-50,00003500650001,H02AB06,1234,1N14D4N0J3,CHEMBL1201199,5865,DB01234,D00232,dexamethasone,Dexamethasone,DEX,地塞米松,地塞米松,上海信谊,国药准字H31021116,84,糖皮质激素,0.75mg,0.75-9mg,1每日1次,1口服;6静脉注射,炎症;脑水肿;恶心呕吐,真菌感染;活动性消化性溃疡,高血压;高血糖;骨质疏松,CYP3A4诱导剂,早晨服用,C,正常剂量,肝功能损害时谨慎,mg,口服,QD,2025-10-06,国家基本药物目录,已验证,长效强效激素
EN007,CA59-46-1,0003-5007-50,00003500750001,G03CA03,10582,E4R4Z2B61Y,CHEMBL1201200,5757,DB00783,D00105,estradiol,Estradiol Valerate,E2V,戊酸雌二醇,补佳乐,拜耳,国药准字J20180030,85,雌激素,1mg;2mg,1-2mg,1每日1次,1口服,绝经综合征;骨质疏松,乳腺癌;子宫内膜癌;静脉血栓,乳腺胀痛;子宫出血,华法林,定期监测乳腺和子宫,X,正常剂量,肝功能损害时禁用,mg,口服,QD,2025-10-06,国家基本药物目录,已验证,HRT首选
EN008,CA57-83-0,0003-5008-50,00003500850001,G03DC02,9997,8W8T17847W,CHEMBL1201201,5994,DB00396,D00182,progesterone,Progesterone,P4,黄体酮,黄体酮胶囊,浙江爱生,国药准字H33020070,86,孕激素,100mg,100-200mg,2每日2次,1口服,黄体不足;先兆流产,肝功能损害;乳腺癌,头晕;乳腺胀痛,无明显相互作用,睡前服用,X,正常剂量,肝功能损害时禁用,mg,口服,BID,2025-10-06,国家基本药物目录,已验证,天然孕激素
EN009,CA86977-65-9,0003-5009-50,00003500950001,G04CB01,40254,H1250JIK0A,CHEMBL1201202,77995,DB01174,D00350,finasteride,Finasteride,FIN,非那雄胺,保法止,默沙东,国药准字J20180031,87,5α还原酶抑制剂,1mg;5mg,1-5mg,1每日1次,1口服,BPH;雄激素性脱发,妊娠;儿童,性功能障碍;乳房发育,无明显相互作用,可与食物同服,X,正常剂量,肝功能损害时谨慎,mg,口服,QD,2025-10-06,国家基本药物目录,已验证,BPH和脱发治疗
EN010,CA84371-65-3,0003-5010-50,00003501050001,G04CA02,35417,8L5014XET7,CHEMBL1201203,5281,DB00241,D00251,tamsulosin,Tamsulosin,TAM,坦索罗辛,哈乐,安斯泰来,国药准字J20180032,88,α1受体阻滞剂,0.2mg,0.2mg,1每日1次,1口服,BPH,低血压;肝功能不全,体位性低血压;射精障碍,CYP3A4抑制剂,餐后服用,B,正常剂量,肝功能损害时禁用,mg,口服,QD,2025-10-06,国家基本药物目录,已验证,BPH首选
